FDA Awards Priority Review Voucher to Rhythm Pharmaceuticals for Rare Pediatric Disease Product IMCIVREE

Summary

The FDA has awarded a priority review voucher to Rhythm Pharmaceuticals, Inc. for its rare pediatric disease product IMCIVREE, following a review of the product's eligibility under the Federal Food, Drug, and Cosmetic Act.